Imbruvica, Gazyva combo meets in Phase III for first-line CLL

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib plus Gazyva obinutuzumab met the primary endpoint of improving progression-free survival (PFS) in the Phase III iLLUMINATE (PCYC-1130) trial to treat previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The open-label, international trial enrolled 212 patients to receive Imbruvica plus Gazyva or chlorambucil plus Gazyva. PFS was assessed by an independent review committee...